Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
29
datasets available to search
ShareScore release 0.9.0
Dataset results
29 results for “Serum Metabolomics”
Characterization of Metabolism Associated with Outcomes in Severe Acute Pancreatitis: Insights from Serum Metabolomic Analysis
<p>1H NMR spectra data of SAP patients (Survivors/ Non-survivors). The spectra were binned as 0.02 ppm spectral buckets. The chemical shift regions corresponding to the water region and TSP were excluded to avoid spectral interference. This dataset was used for the metabolomics related study to highlight the dysregulation of metabolites in the study group.</p> <p> </p>
Mechanistic study on direct and indirect thyroid toxicity in male Wistar rats - Serum Metabolomics
<p>The present oral toxicity study in male Wistar rats is focusing on direct and indirect thyroid<br> toxicity. Biomaterials from this study were used to generate transcriptomics, proteomics,<br> and metabolomics data sets. Featuring a time- and concentration-resolved design<br> including recovery after treatment, this study allows investigating adaptive versus adverse<br> effects in several dimensions.<br> Two well-described test chemicals, i.e., Phenytoin and Propylthiouracil, were administered<br> at each two dose levels to male Wistar rats for 2 (Subset A) and 4 weeks via the diet<br> (Subset B). In addition, a recovery period of 2 weeks without test substance application was<br> included, in order to monitor reversibility of the induced effects (Subset C).<br> During the course of the study, blood samples were taken for metabolome analyses.</p>
Data from: Serum metabolomics predicts treatment response in myasthenia gravis
<p>High-dose prednisone is the primary initial therapy for myasthenia gravis (MG) but upwards of a third of patients do not respond to treatment. No biomarkers can predict clinical responsiveness to corticosteroid treatment. We conducted a discovery-based study to identify treatment responsive biomarkers in MG using sera obtained at study entry to the thymectomy clinical trial (MGTX), an NIH-sponsored randomized, controlled study of thymectomy plus prednisone versus prednisone alone. We applied ultra-performance liquid chromatography coupled with electro-spray quadrupole time of flight mass spectrometry to obtain comparative serum metabolomic and lipidomic profiles at study entry to correlate with treatment response at 6 months. Treatment response was assessed using validated outcome measures of minimal manifestation status (MMS), MG-Activities of Daily Living (MG-ADL), Quantitative MG (QMG) score, or a strictly defined composite measure of response. Increased levels of phospholipids were associated with treatment response as assessed by QMG, MMS, and the Responders classification, but all measures showed limited overlap in metabolomic profiles, in particular the MG-ADL. A panel including histidine, free fatty acid (13:0), <span>γ-</span>cholestenol and guanosine was highly predictive of the strictly defined treatment response measure. The AUC in Responders' prediction for these markers was 0.90. Pathway analysis suggests that xenobiotic metabolism could play a major role in treatment resistance. We have defined a metabolomic and lipidomic profile that can now undergo validation as treatment predictive markers for MG patients undergoing corticosteroid therapy. Distinct metabolomic profiles were appreciated for each outcome measure.</p>
Data from: Serum metabolomics predicts treatment response in myasthenia gravis
Open the record for dataset details and reuse information.
Data from: Fuel stores and time of day account for variation in serum metabolomes of passerine migrants stopping over
Open the record for dataset details and reuse information.
The Urinary Microbiome and Its Relationship to the Urinary and Serum Metabolome in Healthy Peri- and Postmenopausal Women
ClinicalTrials.gov study NCT06573827. IPD Sharing: Not stated. Countries: 1. Publications: 11.
Gut Microbiome and Serum Metabolome Alterations in ADHD Patients
ClinicalTrials.gov study NCT03447223. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Genetic mapping of serum metabolome to chronic diseases among Han Chinese
Open the record for dataset details and reuse information.
Serum metabolome and gut microbiome analysis of Parkinson's disease
<p>Serum metabolomics and gut microbiome analysis of individual with Parkinson's disease (PD) and healthy control</p>
Impact of Pre- and Post-operative Serum Metabolome Dynamics in Colorectal Resection Outcomes
ClinicalTrials.gov study NCT07035262. IPD Sharing: NO. Countries: 1. Publications: 0.
Exploring maternal and developmental toxicity of perfluoroalkyl ether acids PFO4DA and PFO5DoA using hepatic transcriptomics and serum metabolomics
GEO Series GSE266378. Rattus norvegicus. 111 samples. Type: Expression profiling by high throughput sequencing.
Serum metabolomics associating with circulating microRNA profiles reveal the role of miR-383-5p in rat hippocampus under simulated microgravity
GEO Series GSE153681. Rattus norvegicus. 7 samples. Type: Non-coding RNA profiling by array.
Serum and Urine Metabolome Studies in Patients With Acute Kidney Injury After Cardiac Surgery
ClinicalTrials.gov study NCT06245720. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Pre-analytical Sample Handling Conditions and Their Effects on the Human Serum Metabolome
ClinicalTrials.gov study NCT02697500. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Serum Metabolomics Study of Traditional Chinese Medicine Formula （Shen Qi Tiao Ti Formula） Intervention to Polycystic Ovary Syndrome
ClinicalTrials.gov study NCT03623451. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Study on Serum Metabolomics of GDM
ClinicalTrials.gov study NCT05881616. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Serum Metabolomics Study of Polycystic Ovary Syndrome
ClinicalTrials.gov study NCT03618342. IPD Sharing: Not stated. Countries: 1. Publications: 0.
NMR Based Metabolomic Study of Serum Biomarkers in Patients With Parkinson's Disease and Atypical Parkinsonian Syndrome
ClinicalTrials.gov study NCT06490926. IPD Sharing: NO. Countries: 1. Publications: 0.
Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
ClinicalTrials.gov study NCT06540508. IPD Sharing: NO. Countries: 1. Publications: 0.
Gastrointestinal Microflora and Serum Metabolomics in Patients With Pancreatic Cancer and Chronic Pancreatitis
ClinicalTrials.gov study NCT06411470. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.